<style face="normal" font="default" size="100%">Corrigendum to “Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study” [Journal of Critical Care 52 (2019) 75–79](S0883944119300061)(10.1016/j.jcrc.2019.04.013)</style>

Drupal-Bibcite

0<style face="normal" font="default" size="100%">Corrigendum to “Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study” [Journal of Critical Care 52 (2019) 75–79](S0883944119300061)(10.1016/j.jcrc.2019.04.013)</style><style face="normal" font="default" size="100%">Corrigendum to “Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study” [Journal of Critical Care 52 (2019) 75–79](S0883944119300061)(10.1016/j.jcrc.2019.04.013)</style>